Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Registration Number
- NCT06633016
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Brief Summary
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant.
This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo).
The study will include the following stages:
1. Screening, approximately 35 days
2. 42-day Treatment Period
3. 2-week post dose Safety Follow-up Period
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 230
- Meets the DSM-5 criteria for Major Depressive Disorder, with a current major depressive episode duration of > 6 weeks and ≤ 18 months.
- A score of ≤ 22 (midrange mild/moderate) on the Hamilton Anxiety Rating Scale.
- Montgomery-Asberg Depression Rating Scale total score of > 24 [indicating moderate to severe depression] at Screening and at Baseline.
- Subject is compliantly using a single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant for at least 6 weeks for their current episode of depression, with an adequate dose, and with an inadequate response as defined by the Antidepressant Treatment Response Questionnaire. The dosage of the current antidepressant must have been stable for the past 4 weeks, and the dosage and specific antidepressant used should remain the same from Screening through the end of the Follow-up Period.
Note: History implies lifetime history, unless otherwise specified
- History of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features or concomitant DSM-5 depressive disorders, bipolar I or II disorder, cyclothymic disorder, delirium, dementia, amnestic disorder, or cognitive disorder.
- Current diagnosis or active symptoms within the last 2 years of obsessive-compulsive disorder, posttraumatic stress disorder, panic disorder, or eating disorder, according to DSM-5 criteria.
- Primary diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder, according to DSM-5 criteria. Current or history within the last 2 years of self-injurious behavior is exclusionary.
- Has failed more than 2 single selective serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor antidepressant treatments, including the current serotonin reuptake inhibitors / serotonin norepinephrine reuptake inhibitor, during the current depressive episode, despite an adequate dose (per Antidepressant Treatment Response Questionnaire) and duration (at least 6 weeks).
- Failure to respond to triiodothyronine or thyroxine augmentation for the treatment of depression.
- Started new psychotherapy or had a change in the intensity of psychotherapy within 8 weeks before Screening.
- Is suicidal at Screening or Baseline
- History or current evidence within previous 3 months before Screening of uncontrolled, clinically significant neurological, gastrointestinal, respiratory, renal, hepatic, immunological, hematological, or other medical disorder, including cancer, that would jeopardize the safe participation of the subject in the study (in the opinion of the Investigator).
- History of thyroid disease
- History of multiple endocrine neoplasia syndrome
- Diagnosis of epilepsy or history of convulsions, including childhood febrile seizure. Use of co-administered drugs that may lower seizure threshold is excluded.
- Females who are pregnant, intend to become pregnant or are breastfeeding.
- Antidepressants: Prior use of psychedelics, ketamine, or esketamine, for the treatment of Major Depressive Disorder.
- Antidepressants: Current use, or use within 4 weeks prior to Screening, of any other augmentation agents for Major Depressive Disorder (e.g. second-generation antipsychotics [SGA], monoamine oxidase inhibitors [MAOI], tricyclic antidepressants [TCA], lithium, or bupropion)
- Current or prior use of treatment for hypothyroidism including but not limited to synthetic or natural thyroid hormone, triiodothyronine and/or thyroxine.
- Concomitant use of biotin of any dose and in any preparation 14 days prior to Day 1 until after the last study visit at Week 8 (Day 56).
- Medications that are strong cytochrome P450 3A4 inhibitors or strong cytochrome P450 3A4 inducers are not allowed.
- Prescription drug/controlled substance abuse, or illicit substance use within 1 year of Screening or positive urine drug results at Screening or Baseline for an illicit substance.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo + SSRI/SNRI Placebo Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to the Placebo. ABX-002 + SSRI/SNRI ABX-002 Patients continue to receive their selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study in addition to ABX-002.
- Primary Outcome Measures
Name Time Method Change from Baseline in the 17-item Hamilton Rating Scale for Depression (HAMD-17) 6 weeks The HAMD-17 is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. A score of 0-9 is generally accepted to be within the normal range (or in clinical remission), while a score of greater than 17 indicates moderate to severe depression symptoms.
- Secondary Outcome Measures
Name Time Method Change from Baseline for Clinical Global Impression of Severity (CGI-S) 6 weeks a 7-point rating scale used to measure illness and symptom severity in subjects with mental disorders. The greater the number the more severe.
Change from Baseline for Sheehan Disability Scale (SDS) 6 weeks Self-rated, 3-item questionnaire that uses a Likert scale from 0 (not at all) to 10 (extremely) to assess impairment in the occupational, social, and family domains.
Change from baseline for 6-item Hamilton Rating Scale for Depression (HAMD-6) 6 weeks Six-item scale used to assess the core symptoms of depression.
Change from baseline for 29-item Hamilton Rating Scale for Depression (HAMD-29) 6 weeks Clinician-based assessment of depressive symptoms. HAMD-29 covers HAMD-6, HAMD-17 (items 1 to 17), the Melancholia Scale (MES) (items 18 to 23), and the neurovegetative symptoms (NVS) (items 24 to 28).
Patient Global Impression-Improvement (PGI-I) 6 weeks Quality-of-life questionnaire to assess improvement of activities of daily living, wellbeing, and function.
Assessment of safety and tolerability of ABX-002 compared with placebo using adverse events 6 weeks Incidence and severity of treatment-emergent adverse events to ABX-002 will be measured
Trial Locations
- Locations (42)
Autobahn Site #131
🇺🇸Birmingham, Alabama, United States
Autobahn Site #132
🇺🇸Chandler, Arizona, United States
Autobahn Site #116
🇺🇸Phoenix, Arizona, United States
Autobahn Site #136
🇺🇸Tucson, Arizona, United States
Autobahn Site #113
🇺🇸Encino, California, United States
Autobahn Site #133
🇺🇸Encino, California, United States
Autobahn Site #124
🇺🇸Glendale, California, United States
Autobahn Site #140
🇺🇸Long Beach, California, United States
Autobahn Site #121
🇺🇸Los Alamitos, California, United States
Autobahn Site #117
🇺🇸Newport Beach, California, United States
Scroll for more (32 remaining)Autobahn Site #131🇺🇸Birmingham, Alabama, United States